Abstract
Reviewed briefly is the development of a unique vaccine against hCG, which prevents unwanted pregnancy without blocking ovulation and disturbing menstrual regularity. A recombinant version of this vaccine, amenable to largescale production by industry, in both DNA and protein form has been made. Priming with DNA followed by protein improves further its immunogenicity. Mycobacterium indicus pranii (MiP), a cultivable nonpathogenic mycobacteria has been used in the recombinant vaccine as a potent adjuvant. MiP was developed as an immuno-therapeutic vaccine against leprosy. It is approved by the Drugs Controller General of India and USFDA, and has many additional applications in treatment of tuberculosis, curing of ugly ano-genital warts and in prevention and treatment of some cancers.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
